Eintrag weiter verarbeiten
Current challenges and future prospects in oral anticoagulant therapy
Gespeichert in:
Personen und Körperschaften: | , , |
---|---|
Titel: |
Current challenges and future prospects in oral anticoagulant therapy |
In: | British Journal of Haematology, 178, 2017, 6, S. 838-851 |
veröffentlicht: |
Wiley
|
Umfang: | 838-851 |
ISSN: |
0007-1048 1365-2141 |
DOI: | 10.1111/bjh.14714 |
Zusammenfassung: | <jats:title>Summary</jats:title><jats:p>The choice for oral anticoagulant (<jats:styled-content style="fixed-case">OAC</jats:styled-content>) therapy was previously limited to the vitamin K antagonists (<jats:styled-content style="fixed-case">VKA</jats:styled-content>s). The advent of the direct oral anticoagulants (<jats:styled-content style="fixed-case">DOAC</jats:styled-content>s) brought with it the expectation that oral anticoagulation would become simpler (with the elimination of routine monitoring and introduction of a fixed‐dose anticoagulant), and that the use of <jats:styled-content style="fixed-case">VKA</jats:styled-content>s would be slowly phased out. Although <jats:styled-content style="fixed-case">DOAC</jats:styled-content>s have made anticoagulation more convenient and accessible, we are now faced with what can be described as a tyranny of choice, together with many unanswered questions relating to <jats:styled-content style="fixed-case">DOAC</jats:styled-content> use. These include optimal <jats:styled-content style="fixed-case">DOAC</jats:styled-content> selection and dosing, use in complex ‘real‐world’ patients, the role for monitoring and issues surrounding adherence. Warfarin remains the anticoagulant of choice in certain scenarios (e.g. metallic heart valves). The future holds much excitement: clinical studies are underway to expand the indications for <jats:styled-content style="fixed-case">DOAC</jats:styled-content>s and experience continues to grow outside the trials setting.</jats:p> |
Format: | E-Article |
Quelle: | Wiley (CrossRef) |
Sprache: | Englisch |